BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BC Extra | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BC Extra | Nov 19, 2019
Financial News

Wellington's first biotech-focused PE fund raises $393M

Wellington Management has closed its first private equity fund focused on drug discovery and development companies at $393 million. Bob Deresiewicz will manage Wellington Biomedical Innovation Fund I, which was oversubscribed and will invest in...
BC Extra | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

An updated IPO prospectus revealed that BioNTech no longer expects a $100 million contribution to its previously announced series B round from an undisclosed Hong Kong-based investor. The company's initial IPO filing on Sept. 10...
BC Extra | Sep 10, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

BioNTech’s IPO filing revealed that it has not yet received $100 million from a Hong Kong-based investor who was part of its recent $325 million series B round, likely because of “disruptions” in Hong Kong...
BC Extra | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday...
BC Extra | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

FDA panel for Vascepa means likely delay  Amarin Corp. plc (NASDAQ:AMRN) said it expects FDA to extend the PDUFA date for Vascepa icosapent ethyl to late December from Sept. 28 after the agency scheduled an...
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BioCentury | Apr 19, 2019

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
BC Week In Review | Apr 11, 2019
Company News

Hope Medicine in-licenses Bayer’s BAY 1158061

Hope Medicine gained exclusive, worldwide rights from Bayer to develop and commercialize BAY 1158061 to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc. (Beijing,...
Items per page:
1 - 10 of 609